方法：选择于我院住院的120例患者，随机分为两组，每组60例。其中对照

Method: 120 patients who were hospitalized in our hospital were selected and randomly divided into two groups with 60 cases in each group. The control group used conventional GP chemotherapy, and the experimental group used sintilimab injection intravenously on the basis of conventional GP chemotherapy. The serum tumor markers CYFRA211, CEA, CA125 before and after treatment were compared and analyzed between the two groups of patients. The T lymphocyte subsets CD3+, CD4+, CD8+, CD4+/CD8+ change levels, and the clinical efficacy of the two groups of patients at 6 months were compared and analyzed; the results: the serum tumor markers CYFRA211, CEA, and CA125 after treatment in the two groups were all better than those treated The difference is statistically significant (p=0.00), and the decrease in the experimental group is more significant than that of the control group, and the difference is statistically significant (CYFRA211, CA125, p=0.00; CEA, p=0.01; CD3+, CD4+ level experimental group After treatment, it was higher than the control group, which was statistically significant (CD3+, p=0.00; CD4+, p=0.01); CD8+ changes were not significant (p=0.14); CD4+/CD8+ levels in the experimental group were higher than the control group, and the difference was significant (P=0.02); the complete remission rate (CR) of the experimental group was 22%, and the control group was 8%, which was statistically different (p=0.04); the progress rate (PD) of the experimental group was significantly lower than the control group, with statistics Scientific significance (p=0.02), total effective rate (RR) The experimental group has more advantages than the control group, and the difference is statistically significant (p=0.01); Conclusion: Sintilizumab combined with chemotherapy is more effective in the treatment of advanced non-small cell lung cancer Chemotherapy alone can significantly reduce the level of serum tumor markers, improve the cellular immune function of patients, increase the total effective rate of treatment, and reduce the risk of patient progression. It has obvious therapeutic effects. <br>Keywords: Sintilimab, chemotherapy, non-small cell lung cancer , Tumor markers, immune function <br>Introduction:

Methods: The 120 patients who were admitted to our hospital were randomly divided into two groups of 60 patients. In which the control group adopted the conventional GP chemotherapy program, the experimental group used the sedative static point of the single anti-injection of Syndicate on the basis of the conventional GP chemotherapy program, and compared and analyzed the serum tumor markers CYFRA211, CEA, CA125 and T lymphocyte subgroup C in two groups of patients. The change levels of D3 plus, CD4 plus, CD8 plus, CD4 plus /CD8 plus were compared and analyzed with the clinical efficacy of two groups of patients at 6 months; The difference was statistically significant (p-0.00), where the experimental group decreased more significantly than the control group, and the difference was statistically significant (CYFRA211, CA125, p-0.00; CEA, p-0.) 01;CD3-plus, CD4-plus horizontal experimental group was higher than the control group after treatment, which was statistically significant (CD3-plus, p-0.00; CD4-plus, p-0.01), and CD8-plus changed without significance (p-plus). 0.14); CD4-plus/CD8-level experimental group was higher than the control group, the difference was significant (p-0.02), the total mitigation rate (CR) was 22%, the control group was 8%, there was a statistical difference (p-0.04), the progress rate (PD) experimental group was significantly lower than the control group, with statistical significance (P-0.02), the total efficiency (RR) experimental group has more advantages than the control group, the difference is statistically significant (p-0.01); It has obvious therapeutic effect.<br>Keywords: Cyndili monoanti, chemotherapy, non-small cell lung cancer, tumor markers, immune function.<br>Introduction:

Methods: 120 patients in our hospital were randomly divided into two groups, 60 cases in each group. The control group was treated with conventional GP chemotherapy, and the experimental group was treated with cindilimab injection on the basis of conventional GP chemotherapy. The serum tumor markers cyfra211, CEA, CA125, and the levels of CD3 +, CD4 +, CD8 +, CD4 + / CD8 + of T lymphocyte subsets in the two groups before and after treatment were compared and analyzed, and the clinical efficacy of the two groups at 6 months was compared; Results: after treatment, serum tumor markers cyfra211, CEA and CA125 in the two groups were significantly lower than those before treatment (P = 0.00), and the experimental group was more significantly lower than the control group (cyfra211, CA125, P = 0.00; CEA, P = 0.01; CD3 +, CD4 + levels in the experimental group were higher than those in the control group, with statistical significance (CD3 +, P = 0.00; CD) Results: the level of CD4 + / CD8 + in the experimental group was significantly higher than that in the control group (P = 0.02); the complete remission rate (CR) in the experimental group was 22%, which was significantly higher than that in the control group (8%, P = 0.04); the progression rate (PD) in the experimental group was significantly lower than that in the control group, with statistical significance (P = 0.02), and the total effective rate (RR) in the experimental group was better than that in the control group Conclusion: compared with chemotherapy alone, cindilimab combined with chemotherapy in the treatment of advanced non-small cell lung cancer can significantly reduce the level of serum tumor markers, improve the cellular immune function of patients, increase the total effective rate of treatment, and reduce the risk of progression of patients. It has obvious therapeutic effect.<br>Key words: cindilimab, chemotherapy, non-small cell lung cancer, tumor markers, immune function<br>introduction: